6 hasil untuk "Mat Makowski"
Menampilkan 1–6 · 0,24 detik · RSS
-
Artikel Jurnal
Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19
Persistence of Antibody after mRNA-1273 Vaccination A total of 33 participants who received both doses of the Moderna mRNA-1273 vaccine against SARS-CoV-2 had blood drawn over a period of 6 months ...
-
Artikel Jurnal
Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination
Immunogenicity and the mRNA-1273 SARS-CoV-2 Vaccine Thirty-four adults received two 100-μg injections of the mRNA-1273 SARS-CoV-2 vaccine, and serum anti–spike protein and neutralizing antibody tit...
-
Artikel Jurnal
An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
BACKGROUND: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in late 2019 and spread globally, prompting an international effort to accelerate development of a vaccine. The candidate vaccine mRNA-1273 encodes the stabilized prefusion SARS-CoV-2 spike protein. METHODS: We…
-
Artikel Jurnal
Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults
BACKGROUND: Testing of vaccine candidates to prevent infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in an older population is important, since increased incidences of illness and death from coronavirus disease 2019 (Covid-19) have been associated with an older age…
-
Artikel Jurnal Teks lengkap
Remdesivir for the Treatment of Covid-19 — Final Report
BACKGROUND: Although several therapeutic agents have been evaluated for the treatment of coronavirus disease 2019 (Covid-19), no antiviral agents have yet been shown to be efficacious. METHODS: We conducted a double-blind, randomized, placebo-controlled trial of intravenous remdesivir in adults who…
-
Artikel Jurnal Teks lengkap
Durability of mRNA-1273 vaccine–induced antibodies against SARS-CoV-2 variants
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mutations may diminish vaccine-induced protective immune responses, particularly as antibody titers wane over time. Here, we assess the effect of SARS-CoV-2 variants B.1.1.7 (Alpha), B.1.351 (Beta), P.1 (Gamma), B.1.429 (Epsilon), B.1.526…